Innovating Safer Solutions for the Treatment of Metastatic Breast Cancer
Founded in 2015 as an R&D, pre-revenue startup, TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients. TTC Oncology has a license from the University of Illinois at Chicago covering the therapy associated with modulation and mimicry of estrogen actions. TTC Oncology completed a Phase I trial of their proprietary drug at four clinical sites under the guidance of breast cancer oncologists and consultants with extensive experience in pharma and biotech. TTC Oncology has $6.2 million invested toda...
- Security Type
- Min Investment
- Offering Date
- September 10, 2021
- Expected Close Date
- December 09, 2021
Chief Executive Officer
Fundraising that allowed completion of phase 1 clinical trial.
Arkadiusz Dudek, Chief Medical Officer
Completion of Phase 1 clinical trial with TTC352
Debra Tonetti, Chief Scientific Officer
Discovery of biomarker of resistance to hormonal therapy.
No reports have been submittedBecome a Reporter